Decision to list negative pressure wound therapy products supplied by CR Kennedy (NZ) Limited and KCI New Zealand Unlimited
We are pleased to announce the approval of listing agreements with CR Kennedy (NZ) Limited (“CR Kennedy”) and KCI New Zealand Unlimited (“KCI”) for the supply of Negative Pressure Wound Therapy Equipment and Consumables (“NPWT Products”) to DHBs.
What we are doing
We are pleased to announce the approval of listing agreements with CR Kennedy (NZ) Limited (“CR Kennedy”) and KCI New Zealand Unlimited (“KCI”) for the supply of negative pressure wound therapy equipment and consumables (“NPWT Products”) to DHBs.
In summary, this will result in:
- CR Kennedy’s and KCI’s NPWT Products being listed on the Pharmaceutical Schedule from 1 April 2018 under national agreements that all DHBs may purchase or loan under (“Agreements”).
- DHBs being able to continue procuring other suppliers’ brands of NPWT Products.
Any changes to the original proposal?
Who we think will be most interested
- Suppliers and wholesalers
- DHB Staff:
- Wound care clinicians
- Community nursing services
- Clinical engineers
- Procurement officers
Detail about this decision
In June 2017 PHARMAC issued a request for proposals (“RFP”) for NPWT Products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation process, and consulting on the provisional Agreement reached with CR Kennedy and KCI, PHARMAC has decided to list CR Kennedy and KCI’s ranges of NPWT Products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2018.
CR Kennedy’s NPWT Products include the Venturi range of reusable NPWT units for purchase or loan and the associated consumables.
KCI’s NPWT Products include the SNAP disposable mechanical NPWT units and associated consumables for purchase.
The list of products will be available on PHARMAC's website from 1 April 2018, in both a PDF document and an Excel spreadsheet.
DHBs that procure CR Kennedy’s or KCI’s NPWT Products must do so under the terms and conditions, and at the prices, included in the Agreement, from 1 April 2018.
DHBs can continue to choose which NPWT Products they purchase.
The Agreements includes terms and conditions for training and education services to be provided by CR Kennedy and KCI to DHB personnel on the appropriate use of their NPWT Products, which is to be provided at times as agreed with individual DHBs.
CR Kennedy’s Agreement sets out respective supplier and DHB responsibilities for maintenance and management of equipment under the various procurement options.
PHARMAC has been working with a range of suppliers to seek agreements and these Agreement are the latest to arise from that process. Further consultations in this category are expected over the next few months.
Our response to what you told us
We appreciate the time people took to consider this consultation.
All consultation responses received by 2 March 2018 were considered in their entirety in making the decisions to approve CR Kennedy’s and KCI’s provisional Agreements.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
|DHB request for in-service and information about indications and contraindications of SNAP NPWT therapy, and for pricing||KCI||PHARMAC expects suppliers to provide relevant training and education to DHBs that are considering using their products, at times and in formats agreed with the DHBs. Pricing information has been provided to DHB procurement managers and will be available on PHARMAC’s website from 1 April 2018.|
|No technical or resource impacts are anticipated as a result of the proposals.||CR Kennedy
If you have any questions about these decisions, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.